Abstract:Introduction Beta-blockers (BBs) and angiotensin receptor blockers (ARBs) have been proved to decrease the growth rate of the aortic root in Marfan patients, we describe our single centre experience at a large tertiary paediatric institution. Methods This is a retrospective longitudinal study of a large, paediatric only, Marfan cohort through review of medical notes for clinical data and treatment and assessment of serial echocardiograms. Results 167 patients were included, mean age at first assessment was 4.05 ± 3.12 years, 86 (51.50%) were males. 41 pts (24.55%) had a de novo FBN1 mutation. A 35.32% had a cysteine loss mutation. Median follow up was 9.54±4.37 years. 2 patients had a clinical and molecular diagnosis of early-onset Marfan, they both underwent mitral valve surgery in infancy and one of them died at 7 years old. No other deaths or acute aortic events in our cohort until transition to adult services at 18 years old. Of the entire study population 12 pts (7.2%) underwent aortic surgery at a median age of 13±7.02 years, 1 patient had a mitral valve repair. Chemoprophylaxis (currently only evaluated in a subgroup of our youngest 65 patients) was offered to all patients, 27.69% declined medicines. The remining 47 subjects are on treatment which was started at a mean age of 4.88 ±2.96 years, surveillance data available for a mean follow up of 2.75±2.41 years. 50 received BB (58.50% atenolol [average dose 0.79 mg/kg/day] and 19.15% bisoprolol [average dose 0.087 mg/kg/day]), 5 (8.51%) losartan [average dose 0.763 mg/kg/day], and 10 (15.38%) double therapy with BB and ARBs. The Sinus of Valsalva (SOV) z-scores, as assessed on echocardiograms and normalised according to Lopez dataset, showed a reduction over time in children treated with chemoprophylaxis (see figure 1). SOV mean z-score at starting treatment was 3.38 ± 2.06 which reduced to 2.79± 1.81, however, differences were not statistically significant (paired T-student p-value 0.078). In non-treated patients, initial SOV z-score was 1.89 ± 1.05. When comparing evolution there was a trend towards decreased average SOV z-score over the years in the treated group, not seen in the non-treated patients (see figure 2). No statistical differences in the SOV z-score reduction change were found when comparing different treatment groups (ANOVA p-value 0.851), but a tendency to more profound decrease in the losartan groups was observed. Reduction in blood pressure or heart rate did not differ amongst the treatment groups. Conclusions We present one of the largest single centre reviews on management of paediatric Marfan patients. Our data confirm a decrease in SOV z-score with chemoprophylaxis in a real-world cohort. This is in line with current evidence and corroborates clinical practice.SOV Z-SCORE EVOLUTION AFTER TREATMENTSOV Z-SCORE GROUP AVERAGE CHANGE

Right ventricular function in marfan patients remains stable despite multiple cardiac interventions

Mitral Valve Repair for Mitral Regurgitation in Patients With Marfan Syndrome

Mitral valve surgery in patients with Marfan syndrome

Echocardiographic right ventricular evaluation in cardiac surgery patients undergoing mitral valve reconstruction: a single center prospective observational study

Aortic Regurgitation in Marfan Syndrome Patients Who Underwent Prophylactic Surgery: A Single-Center Experience.

The effect of pulmonary hypertension and right ventricular dysfunction on early mortality and morbidity in patients undergoing mitral valve replacement

Abnormal Cardiac Magnetic Resonance–Derived Ascending Aortic Area Strain Demonstrates Altered Ventriculo-Vascular Function in Marfan Syndrome

Comparative Analysis of Long-Term Outcomes in Thoracoabdominal Aortic Aneurysm Repair Between Marfan Syndrome and Non-Marfan Syndrome Patients

Right ventricular systolic function in severe tricuspid regurgitation: prognostic relevance of longitudinal strain

Preoperative risk factors of medium-term mitral valve repair outcome

Endovascular Treatment of Aortic Pathologies in Patients With Marfan Syndrome: Single-Center Experience

Marfan syndrome in children: large, single centre experience on management and outcome

Surgical Treatment for 32 Cases of Marfan's Syndrome

Factors for development of late significant tricuspid regurgitation after mitral valve replacement: the impact of subvalvular preservation

Tricuspid Regurgitation Severity after Atrial Septal Defect Closure or Pulmonic Valve Replacement.

Challenges in prompt identification and surgical correction of Marfan Syndrome aortic disease in a middle-income country: a case series study

Early and late Results after Surgical Mitral Valve Repair: A High-Volume Center Experience

P1755 Clinical and echocardiographic outcomes of mitral valve repair surgery

P3655Right Ventricular Volume Off-Loading Following Atrial Septal Defect Closure or Pulmonary Valve Replacement: Impact on Tricuspid Regurgitation and Mid-Term Remodeling

Natural history and mid-term prognosis of severe tricuspid regurgitation: A cohort study

Tricuspid regurgitation in the context of severe left-sided valvular disease: Patients characteristics and outcome